Literature DB >> 26752680

A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia.

Srinivas K Tantravahi1, Philippe Szankasi2, Jamshid S Khorashad1, Kim-Hien Dao3, Tibor Kovacsovics1, Todd W Kelley2, Michael W Deininger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26752680      PMCID： PMC5152569          DOI： 10.3109/10428194.2016.1138295

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  16 in total

1.  Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

Authors:  Alexander Kohlmann; Vera Grossmann; Hans-Ulrich Klein; Sonja Schindela; Tamara Weiss; Beray Kazak; Frank Dicker; Susanne Schnittger; Martin Dugas; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

2.  Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.

Authors:  Kristen Meldi; Tingting Qin; Francesca Buchi; Nathalie Droin; Jason Sotzen; Jean-Baptiste Micol; Dorothée Selimoglu-Buet; Erico Masala; Bernardino Allione; Daniela Gioia; Antonella Poloni; Monia Lunghi; Eric Solary; Omar Abdel-Wahab; Valeria Santini; Maria E Figueroa
Journal:  J Clin Invest       Date:  2015-03-30       Impact factor: 14.808

Review 3.  Current status of allogeneic HST for chronic myelomonocytic leukemia.

Authors:  H Cheng; V G Kirtani; U Gergis
Journal:  Bone Marrow Transplant       Date:  2011-07-11       Impact factor: 5.483

4.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

5.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

6.  Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.

Authors:  M M Patnaik; E Padron; R R LaBorde; T L Lasho; C M Finke; C A Hanson; J M Hodnefield; R A Knudson; R P Ketterling; A Al-kali; A Pardanani; N A Ali; R S Komrokji; R S Komroji; A Tefferi
Journal:  Leukemia       Date:  2013-03-27       Impact factor: 11.528

7.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

Review 8.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

9.  A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.

Authors:  E Wattel; A Guerci; B Hecquet; T Economopoulos; A Copplestone; B Mahé; M E Couteaux; L Resegotti; V Voglova; C Foussard; B Pegourié; J L Michaux; E Deconinck; A M Stoppa; G Mufti; D Oscier; P Fenaux
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

10.  Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.

Authors:  Esperanza Such; Ulrich Germing; Luca Malcovati; José Cervera; Andrea Kuendgen; Matteo G Della Porta; Benet Nomdedeu; Leonor Arenillas; Elisa Luño; Blanca Xicoy; Mari L Amigo; David Valcarcel; Kathrin Nachtkamp; Ilaria Ambaglio; Barbara Hildebrandt; Ignacio Lorenzo; Mario Cazzola; Guillermo Sanz
Journal:  Blood       Date:  2013-01-31       Impact factor: 22.113
View more
  11 in total

Review 1.  Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael W N Deininger; Jeffrey W Tyner; Eric Solary
Journal:  Nat Rev Cancer       Date:  2017-06-23       Impact factor: 60.716

2.  5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice.

Authors:  Andriyana K Bankova; Wendy W Pang; Brenda J Velasco; Janel R Long-Boyle; Judith A Shizuru
Journal:  Blood Adv       Date:  2021-10-12

3.  Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis.

Authors:  Xinhui Zheng; Liwei Lv; Xiangjun Li; Erlie Jiang
Journal:  Glob Med Genet       Date:  2022-04-08

4.  Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia.

Authors:  John C Molina; Julie M Asare; Laura Tuschong; Robert R West; Katherine R Calvo; Rebecca Persky; Alison M Boyce; Dima A Hammoud; Steven M Holland; Dennis Hickstein; Nirali N Shah
Journal:  Pediatr Blood Cancer       Date:  2020-12-27       Impact factor: 3.838

5.  Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet.

Authors:  Raphael Itzykson; Pierre Fenaux; David Bowen; Nicholas C P Cross; Jorge Cortes; Theo De Witte; Ulrich Germing; Francesco Onida; Eric Padron; Uwe Platzbecker; Valeria Santini; Guillermo F Sanz; Eric Solary; Arjan Van de Loosdrecht; Luca Malcovati
Journal:  Hemasphere       Date:  2018-11-29

Review 6.  Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?

Authors:  Konstantinos Liapis; Ioannis Kotsianidis
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

7.  A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm.

Authors:  Peng Li; Shobi Venkatachalam; Daniela Ospina Cordona; Lorena Wilson; Tibor Kovacsovics; Karen A Moser; Rodney R Miles; David B Beck; Tracy George; Srinivas K Tantravahi
Journal:  Blood Adv       Date:  2022-01-25

8.  Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study.

Authors:  Yu Xu; Rong Guo; Miao Miao; Guangsen Zhang; Jianping Lan; Jie Jin
Journal:  Invest New Drugs       Date:  2022-07-14       Impact factor: 3.651

9.  Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.

Authors:  Hein Than; Yi Qiao; Xiaomeng Huang; Dongqing Yan; Jamshid S Khorashad; Anthony D Pomicter; Tibor J Kovacsovics; Gabor T Marth; Thomas O'Hare; Michael W Deininger
Journal:  Leukemia       Date:  2018-03-27       Impact factor: 11.528

10.  A Case of Synchronous Bone Marrow Chronic Myelomonocytic Leukemia (CMML) and Nodal Marginal Zone Lymphoma (NMZL).

Authors:  Paolo K Soriano; Taylor Stone; Junaid Baqai; Sherjeel Sana
Journal:  Am J Case Rep       Date:  2018-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.